Sodium 4-phenylbyrate rescues glucocorticoid-induced ocular hypertension by reducing abnormal ECM deposition in the TM via activation of MMP9

Date

2020

Authors

Kasetti, Ramesh
Maddineni, Prabhavathi
Zode, Gulab

ORCID

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Purpose: Ocular hypertension (OHT) is a serious side effect of glucocorticoid (GC) therapy and if left undiagnosed, it leads to glaucoma. Previously, we have shown that, sodium-4-phenylbutyrate (PBA) rescues GC-induced OHT. However, the exact mechanism behind PBA mediated reduction of GC-induced OHT is not completely understood. Here, we examined whether PBA rescues GC-induced OHT by reducing abnormal ECM deposition via activating MMP. Methods: GC-induced OHT mice were topically instilled 1% PBA or vehicle twice daily. IOPs and outflow facility were analyzed. Immunostaining, western blot and qPCR were performed to analyze the effect of PBA on GC-induced ECM deposition and ER stress in primary human TM cells, mouse and ex-vivo cultured human TM tissues. Effect of PBA on MMP's activity was analyzed by zymography. Results: Topical PBA eye-drops reduced GC-induced OHT and improved outflow facility significantly. PBA reduced GC-induced intracellular and extracellular ECM accumulation, and prevented induction of ER stress in primary human TM cells, ex-vivo human cultured TM tissues and mouse TM tissues. We observed that PBA can reduce existing ECM deposition when primary TM cells were grown on decellularized GC-treated ECM. Gene expression, western blot and zymography assays revealed that PBA induces increased expression and activity of MMP-9. Inhibition of MMP-9 activity by chemical-inhibitors abrogated PBA's effect on ECM reduction. Conclusions: PBA can be a very attractive treatment for general POAG via targeting abnormal ECM accumulation in the TM.

Description

Keywords

Citation

Rights

License

Collections